Saturday 17 October 2026
Export CELC’s income statement to Excel — free account
Celcuity, Inc.
CELC Healthcare Biotechnology
In the quarter to June 2026, EPS fell 38.5%, free cash flow fell 53.3% and total debt rose 658.7%, each against the same quarter a year earlier.
56.16
4.14
−6.87%
Follow CELC
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (1,433.70%) | (275.17%) | (163.80%) | (122.04%) |
+8 more TTM periods Free account |
|
| (44.77%) | (61.40%) | (49.75%) | (43.45%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(32.84%) | (51.25%) | (41.95%) | (37.23%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(3.51) | (3.18) | (3.28) | (3.04) | |
Free Cash Flow |
(192.28) | (172.97) | (153.53) | (144.89) | |
Capital Expenditures |
(0.57) | (0.47) | (0.25) | (0.24) | |
| Other line items | |||||
Cash ROIC |
(12.87%) | (22.64%) | (17.77%) | (16.24%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(9.37) | (9.30) | (10.04) | (11.18) | |
Operating CF/Net income |
0.85 | 0.89 | 0.87 | 0.89 | |
Depreciation/Fixed assets |
7.71 | 6.49 | 6.62 | 6.16 | |
Capex/Depreciation |
(0.12) | (0.12) | (0.08) | (0.09) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(3.50) | (3.17) | (3.28) | (3.04) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates